Author

V. L. D. Bonato

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

C. A. Fuzo· 2 shared M. Dias-Baruffi· 2 shared A. Teixeira-Carvalho· 1 shared C. Becari· 1 shared E. A. Neto· 1 shared F. L. A. C. Mestriner· 1 shared G. F. Correa· 1 shared J. Coelho-dos-Reis· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

C. A. Fuzo

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Airway epithelial cells and macrophages trigger IL-6-CD95/CD95L axis and mediate initial immunopathology of COVID-19

T. F. Fraga-Silva, U. G. Cipriano, M. J. Fumagalli, G. F. Correa, C. A. Fuzo, F. L. A. C. Mestriner, C. Becari, A. Teixeira-Carvalho, J. Coelho-dos-Reis, M. G. Menegueti, L. T. M. Figueiredo, O. A. Martins-Filho, M. Dias-Baruffi, M. Auxiliadora-Martins, R. C. Tostes, V. L. D. Bonato

This study identifies the IL-6-CD95/CD95L axis as a key driver of immunopathology in severe COVID-19 through interactions between airway epithelial cells and macrophages.

bioRxiv · Aug 22, 2022Immunology

Drug repurposing to face Covid-19: Celastrol, a potential leading drug capable of inhibiting SARS-CoV-2 replication and induced inflammation

C. A. Fuzo, R. B. Martins, T. F. C. Fraga-Silva, M. K. Amstalden, T. Canassa-DeLeo, J. P. Souza, T. M. Lima, L. H. Faccioli, S. C. Franca, V. L. D. Bonato, E. A. Neto, M. Dias-Baruffi

This paper identifies celastrol as a potential drug for treating Covid-19 by inhibiting SARS-CoV-2 replication and reducing IL-6 secretion in infected cells.

bioRxiv · Apr 20, 2021Immunology